A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: Design of the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T (RAPID-TnT) study by Papendick, Cynthia et al.
  	

A randomised trial of a 1-hour troponin T protocol in suspected acute
coronary syndromes: Design of the Rapid Assessment of Possible ACS In the
emergency Department with high sensitivity Troponin T (RAPID-TnT) Study
Cynthia Papendick, Andrew Blyth, Anil Seshadri, Michael JR Edmonds, Tom
Briffa, Louise Cullen, Stephen Quinn, Jon Karnon, Anthony Chuang, Adam J
Nelson, Matthew Horsfall, Erin Morton, Derek P Chew
PII: S0002-8703(17)30145-X
DOI: doi: 10.1016/j.ahj.2017.05.004
Reference: YMHJ 5446
To appear in: American Heart Journal
Received date: 10 March 2017
Accepted date: 14 May 2017
Please cite this article as: Papendick Cynthia, Blyth Andrew, Seshadri Anil, Edmonds
Michael JR, Briﬀa Tom, Cullen Louise, Quinn Stephen, Karnon Jon, Chuang Anthony,
Nelson Adam J, Horsfall Matthew, Morton Erin, Chew Derek P, A randomised trial of a
1-hour troponin T protocol in suspected acute coronary syndromes: Design of the Rapid
Assessment of Possible ACS In the emergency Department with high sensitivity Troponin
T (RAPID-TnT) Study, American Heart Journal (2017), doi: 10.1016/j.ahj.2017.05.004
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
A randomised trial of a 1-hour troponin T protocol in suspected 
acute coronary syndromes: Design of the Rapid Assessment of 
Possible ACS In the emergency Department with high sensitivity 
Troponin T (RAPID-TnT) Study. 
RCT# ACTRN12615001379505 
 
Cynthia Papendick1, Andrew Blyth2.3, Anil Seshadri2,3, Michael JR Edmonds3, 
Tom Briffa4, Louise Cullen5,6,7, Stephen Quinn8, Jon Karnon1, Anthony 
Chuang2,3, Adam J Nelson1, Matthew Horsfall3, Erin Morton2, Derek P Chew2,3 
 
Author Affiliations 
1. School of Medicine, University of Adelaide, Adelaide, Australia 
2. School of Medicine, Flinders University of South Australia, Adelaide, 
Australia 
3. South Australian Department of Health, Adelaide, Australia 
4. School of Population and Global Health, University of Western 
Australia, Perth, Australia 
5. Dept. of Emergency Medicine, Royal Brisbane and Women’s Hospital 
6. School of Public Health, Queensland University of Technology 
7. School of Medicine, University of Queensland.  
8. Department of Statistics, Data Science and Epidemiology, Swinburne 
University of Technology 
 
 
Running Title: Design of RAPID-TnT RCT in the ED 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
Word Count:  Abstract: (257), Text incliuding tables, legends and references: 
(total: 5385), 
References: 27 
Key Words: Troponin, Myocardial Infarction, Chest pain assessment, Clinical 
Trial 
Corresponding Author 
 Derek P Chew MBBS MPH 
 Flinders University 
 Flinders Drive, Bedford Park 
 South Australia, 5042 
 AUSTRALIA 
 Ph:   +618 8404 2001 
 Fax:   +618 8404 2150  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
Abstract (260) 
Background:  Protocols incorporating high sensitivity troponin to guide 
decision making in the disposition of suspected ACS patients in the 
emergency department (ED)  have received a lot of attention.  Traditionally, 
chest pain patients have required long periods of observation in ED before 
being deemed safe for discharge.  In an era of limited health service 
resources, a protocol that could discharge patients safely within an hour of 
presentation is extremely attactive. Unfortunately, despite incorporation into 
some guidelines, these protocols have not been subjected to randomized 
comparisons evaluating safety, effectiveness and cost-effectiveness.   
Objective: This study is designed to provide the evidence required to allow 
key decision makers to implement these protocols.   Specifically, to provide 
evidence that a decision-rule based on 0 and 1 hour high-sensitivity 
troponin T (hs-TnT) is safe, provides non-inferior outcomes in all suspected 
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ACS patients, and that implementation of a rapid troponin protocol leads to 
efficient care.   
Design: This prospective pragmatic trial (n=5400, 5 hospitals) randomly 
allocates suspected ACS patients to either a 0/1-hour hs-TnT protocol as 
advocated in clinical guidelines, versus usual care of standard troponin 
reporting evaluated at 3 and 6 hours. The primary effectiveness composite 
endpoint of this study is all-cause death, new/recurrent ACS within 30 days. 
To evaluate cost-effectiveness, follow-up will determine clinical events, 
quality of life and resource utilizationwithin 12-months.  
Summary:    Demonstrating that a 0/1 hour hs-TnT protocol improves the 
effectiveness and efficiency of care within a robust comparative study, will 
fill an evidence gap that currently limits the translation of more precise hs-
TnT testing into better patient and health service outcomes. (Reg. 
No.ACTRN12615001379505) 
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Introduction 
Health services are replete with innovations promising improvements in care 
and outcome.(1) Realizing these benefits requires parallel evolution of 
clinical decision-making, supported by objective, validated evidence. 
Improvements in troponin test performance are one such innovation, with 
the potential to disposition of emergency department (ED) patients 
presenting with suspected Acute Coronary Syndromes (ACS) by facilitating 
earlier recognition of NSTEMI, thereby reducing treatment delay, and 
through ruling-out ACS allowing earlier discharge.  Unfortunately clinical 
evidence has not kept up with the rate of biochemical assay advancement.  
The vast majority of high-sensitivity troponin testing data focuses on test 
performance, rather than the prospective and randomized evaluation of its 
impact on clinical outcome.(2,3) Furthermore, international data continue to 
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suggest that widespread unguided implementation of high-sensitivity 
troponin testing in EDs is not cost-effective.(4,5)  
Nevertheless, protocols utilizing the change in troponin over 1-hour from 
hospital presentation using high-sensitivity troponin assays have been 
developed and are advocated in the European Society of Cardiology 
Guidelines for the management of non-ST segment elevation ACS.(6,7) 
These protocols suggest that up to 60% of patients may be safely 
discharged from the ED more rapidly than traditional care.  To date, current 
large published studies using one hour protocols have been 
observational.(7,8) These studies have not evaluated prospective patients 
clinically managed according to the troponin protocols and did not include a 
randomized control.  To address this, we have designed and initiated a 
pragmatic randomised trial that will comprehensively evaluate the safety, 
clinical effectiveness and resource implications of a 1-hour protocol using 
high-sensitivity troponin T (hs-TnT) in the care of suspected ACS patients.  
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Methods 
Primary Objective and Hypothesis  
The primary aim of this study is to determine the relative effectiveness of a 
0/1-hour hs-TnT protocol compared with current standard care for 
suspected ACS patients within the ED in terms of 30-day all-cause mortality 
or new/recurrent ACS admission. Secondary aims are to determine if 
suspected ACS patients discharged from the ED in accordance with a 0/1-
hour hs-TnT protocol have an acceptably low rate of death or new/recurrent 
acute coronary syndrome (ACS) by 30 days, compared to the existing 
treatment, and to evaluate the health system cost effectiveness of a hs-TnT 
based strategy at 12 months. 
The primary hypothesis is that in comparison to standard care utilising 
conventional TnT reporting, risk assessment and clinical care based on a 0-
hour/1-hour hs-TnT protocol will provide non-inferior clinical outcomes at 
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30 days, with less total cost at 12 months. The secondary hypothesis is that 
clinical management of patients with suspected ACS discharged from the ED 
under the 1-hour hs-TnT protocol is safe with a 30-day death or 
new/recurrent ACS pf <1%. 
 
Study Design 
This is a prospective randomised trial (n=5400, 5 hospitals) of the ESC 
guideline-advocated TRAPID-AMI 1-hour hs-TnT protocol for 
undifferentiated chest pain.(6,7) (Figure 1) To maintain the integrity of the 
testing protocols in each study arm, randomization to troponin reporting 
formats will occur before any troponin assays are undertaken. The primary 
composite endpoint is all-cause death or new/recurrent ACS by 30 days, and 
clinical events will also be determined within 12 months of follow-up. 
Participant eligibility is described in Table 1. This study is registered with 
Australian and New Zealand Clinical Trial Registry. (Reg. 
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No.ACTRN12615001379505).  
 
Intervention: Clinical disposition and care determined by the hs-TnT result 
For patients randomised to the 0/1 hour hs-TnT protocol, hs-TnT report 
results will determine the patients care pathway. Baseline and a 1-hour hs-
TnT formatted sample will determine the patient’s disposition based on the 
TRAPID-AMI protocol (Figure 2): (a) Rule-out: baseline troponin <5ng/L or 
<12ng/L and change in troponin over 1 hour of <3ng/L: discharge to 
primary care with instructions regarding repeat episodes of chest pain and 
primary prevention advice; (b) Rule-in: baseline troponin ≥ 52ng/L or a 
change over 1 hour of ≥ 5ng/L: Admit to hospital for management of MI; (c) 
Observe: baseline troponin between 13-51 ng/L and a change over 1 hour of 
< 5ng/L, or baseline troponin of <12ng/L and a change over 1 hour of 3-
4ng/L, will be admitted to an inpatient unit.(7)  Subsequent testing will be 
determined by treating clinicians although application of the National 
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Institute for Health and Care Excellence [NICE] guidelines will be 
recommended. (9) These guidelines make recommendations regarding 
functional or invasive coronary testing based on characterisation of chest 
pain and cardiovascular risk factors. 
 
Control Arm: Current standard of care 
Based on current and emerging guidelines, patients randomized to standard 
care will receive troponin testing at baseline, and repeated at 3 hours after 
presentation (with further testing at clinician discretion), with results 
reported according to the conventional lower reference limit (30ng/L).(10) 
Patients randomised to the best current care will have their disposition 
determined by the treating ED clinician. The control arm report does not 
have sufficient troponin profile information to safely implement the 1-hour 
protocol, preventing contamination between randomised study arms. 
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Access to outpatient care will be as per local practice. Subsequent care will 
be physician-determined. 
 
Controlling Exposure of the hs-TnT reporting 
Potential study participants will be identified by a senior ED clinician and 
trial eligibility will be assessed at the end of the initial medical assessment. 
The enrolling and/or treating physician will complete the EDACS risk scoring 
information.(11)  Consenting patients will be randomly allocated to either the 
current conventional troponin T report and physician-directed care, or the 0-
hour/1-hour hs-TnT determined management care pathway. Block 
randomization in blocks of 4 within hospital sites will be performed to 
ensure balance between study arms by location. The randomization 
schedule will be generated by an independent statistician and will be 
implemented by a sealed envelope process.   
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Pathology services for all South Australian public hospitals is provided by a 
centralized provider (SA Pathology), enabling uniformed management of the 
two troponin reporting formats.  The Roche Diagnostics (Cobas) Elecsys 5th 
generation hs-TnT assay (detection limit: 3 ng/L, 99th percentile: 14 ng/L) 
has been in use since April 2010.  However, SA Pathology currently reports 
troponin results to levels numerically aligned with the 4th generation assay 
(i.e. normal 30ng/L, with levels <30 ng/L reported as “≤29 ng/L”) rather 
than the absolute level. While it is recognized that a level of 30ng/L is 
comparable to ~50ng/L using the 4th generation assay, clinical decision-
making based on this level is now established in practice.(12) Furthermore, 
while the clinical use of the more sensitive troponin level does potentially 
narrow the contrast between the study arms, the potential value of the 0-
hour/1-hour protocol under investigation, resides in its ability to leverage 
small changes in troponin at early time points to aide clinical decision-
making, and a characteristic that is not present in the control arm.  The  5th 
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generation hs-TnT reporting format will only be reported for those patients 
randomized to the investigational management arm.  
 
Data Collection and Outcome Measures 
All patients will be followed to assess the frequency of  diagnostic 
procedure(s)/service(s) at intial presention and during follow-up (e.g. stress 
testing, echocardiography, invasive investigation and revascularization), ED 
length of stay (LOS), inpatient health care/total LOS, outpatient health care 
attendance(s) (i.e general practioner and specialist attendances), 
readmission(s), as well as the use of guideline-recommended 
pharmacotherapies.Patients will be assessed for ED and total hospital length 
of stay, readmission and all aspects of resource utilisation including ongoing 
imaging and pathology services.  At 30 days, 6 months and 12 months, 
patients will be contacted by telephone and assessed for vital status, 
rehospitalisation and quality of life (EQ-5D). Evidence of South Australian 
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readmissions will be sourced from centralised public and private South 
Australian hospital data.   
The primary effectiveness measure will be the incidence of composite of all-
cause mortality new/recurrent ACS (i.e. readmission for MI or unstable 
angina) within 30 days of randomization. Key secondary endpoints will be 
the incidence of primary endpoint composite by 12 months, components of 
the primary endpoint by 30 days and 12 months, and cardiovascular 
rehospitalisation, bleeding events and resource utilization for health 
economic evaluation. The definition of outcome measures are described in 
table 2.  Enrolment commenced in December 2015 and there are currently 
796 randomized within the study from 2 centres.  The anticipated “last 
patient-in” is December 2018, with “last patient-out” of 30 day follow-up in 
January 2019, and last patient-out of 12 month follow-up in January 2020. 
Baseline clinical characteristics and measures of protocol adherence are 
presented in table 3. 
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Ethical Considerations and Study Governance 
Ethics approval has been received from the Southern Adelaide Clinical 
Human Research Ethics Committee, with mutual acceptance covering all 
other sites involved. All patients will be asked to provide informed consent. 
The steering committee of emergency physicians, emergency and cardiology 
nurses, cardiologists, implementation experts and clinical pathologists with 
representation from each of the participating hospitals is providing 
oversight to the study. Data management is centralized at Health Systems 
Research group of Flinders University. An independent Data and Safety 
Monitoring Board (DSMB) is reviewing all in-hospital and post-discharge 
(≤7days) clinical events including representations to hospital.  A Clinical 
Event Adjudication Committee, independent of the study management team 
is providing blinded evaluation (events de-identified for treatment arm, 
hospital and patient details) of all components of the primary endpoint 
including index (within 24 hours of initial presentation) and subsequent MI.  
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The study will employ frequent DSMB review of events rates to ensure 
patient safety, leveraging the existing administrative data infrastructure to 
facilitate event adjudication. 
Study funding: This is an investigator-initiated study funded by the National 
Health and Medical Research Council of Australia (APP1124471) with 
additional funding through an unrestricted grant from Roche Diagnostics 
(Basel Switzerland). Roche Diagnostics were approached after the study was 
designed, ethical approval gained and enrolment commenced, and their 
contribution was not dependent on any protocol modification or direct 
access to the study data.  
 
Sample Size Determination 
An earlier study published by in this population observed primary endpoint 
30-day rate of 2.1% [20/945] for all patients, and 1.5% [12/811] among those 
with an initial troponin <30ng/L under the standard arm.(13) Apporximately 
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40% of patients were discharged directly from the ED. The event rate among 
those discharged directly from ED within the hs-TnT arm of this  study was 
0.3% [1/368] while in TRAPID-AMI it was 0.1%.(7) In the TRAPID-AMI study, 
direct discharge from the ED was reported in ~60% of patients. In addition, 
ED physicians report an “acceptable”  30-day missed death or MI rate of less 
than 1%.(14)  Consequently, assuming a primary endpoint in the active arm 
of 0.3%, and a 60%:40% ED discharge ratio, a sample size of 1212 ED 
discharged patients in the active arm and 808 ED discharged patients in the 
control arm (total n= 2020) provides 80% power to demonstrate the non-
inferiority of hs-TnT to standard-TnT, assuming a “clinically acceptable 1% 
absolute rate” (i.e. non-inferiority margin of 0.7%).  
However, Several other factors required further consideration in the sample 
size estimation. First, a further 2020 patients not discharged from the ED 
(i.e.those 40% and 60% of patients admitted, died, and transferred) 
contribute to the primary analysis (total n=4040). Second, our previous 
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experience has shown that 22% of patients present with a troponin ≥30ng/L, 
and since these patients receive little difference in reporting protocols and 
care between study arms, this dilutes study power. Accounting for these 
patients and a 3% attrition rate by 12 months as previously seen, a sample 
size of 5400 is planned. Third, with very low event rates, relative effect sizes 
have limited clinical relevance. Hence, an absolute effect size based on a 
“number needed to treat” under the new protocol of 100 (i.e. 1% absolute 
reduction) has been chosen as an addition design goal. If the control arm 
event rate is as low as 1.5% among patients with troponin <30ng/L, this 
sample size (n=5400) has 80% power to detect a 1% absolute reduction (i.e. 
27 fewer events) in the 30-day primary endpoint and 86% power to detect 
this same absolute reduction (i.e. 21 fewer events) among patients with an 
initial troponin <30ng/L (n=4040). The study has > 80% power to 
demonstrate that for 12-month follow-up the hazard ratio for time to the 
primary endpoint between the two groups is no worse than 2. An interim 
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analysis to assess the overall primary endpoint event rate among patients 
discharged from the ED in the active arm will be conducted at 2000 patients 
(i.e. estimated 750 patients discharged from the ED under the active arm) to 
assess safety of discharge under the 0-hour/1-hour protocol and overall 
events rates. 
Assuming no difference in quality of life, and a standard deviation in costs of 
$3000, the health economic analysis has > 90% power to detect a difference 
of $650 dollars per patient assessed. All sample size calculations assume a 
Type I error rate of 5%. 
 
Methods of Statistical Analyses 
The primary analysis will employ the intention-to-treat (ITT) population 
including all randomised patients.  Given the non-inferiority design of 
secondary safety question, this analysis will use the per-protocol population 
defined as protocol compliant and discharged from ED, with a sensitivity 
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analysis undertaken using the ITT population. The study will be reported 
according to CONSORT guidelines. Overall effectiveness of care under the 
0/1-hour hs-TnT protocol compared with standard care will be assessed 
using negative binomial regression with robust standard errors. Twelve-
month freedom from mortality, recurrent ACS will be assessed by Cox 
regression survival analysis using shared frailty models to account for 
correlated results within hospitals.  Comparisons of the proportions of 
patients receiving various investigations and revascularisation will be 
compared using univariate and multivariate random effects logistic 
regression, again clustering over hospitals. Further, sub-analysis will be 
confined to patients with an initial troponin <30ng/L, i.e. in the range where 
troponin reporting format (e.g. actual level 5-29ng/L versus ≤29ng/L) differs 
between the two study arms. The key secondary non-inferiority analysis will 
determine if the incidence rate among the patients discharged under the 
0/1 hour hs-TnT protocol is not inferior to the accepted ED standard of 1.0% 
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by examining whether upper confidence bound of the incidence rate 
difference crosses 0.7%.  
Economic Analysis: Analysis will be undertaken from the viewpoint of the 
health funders (i.e. State Health Departments [DRGs], Medicare Benefits 
Scheme [MBS] and Pharmaceutical Benefit Scheme [PBS]). Within-trial 
incremental costs associated with hs-TnT reporting compared with the 
conventional TnT report will be estimated using federal reimbursments for 
primary care (MBS), pharmaceutical (PBS), and private hospital costs (DRG), 
and centralised costing data for inpatient and outpatient episodes at public 
hospitals (DRG). Within-trial cost-effectiveness with respect to the primary 
clinical outcome and quality adjusted life years (QALYs) will be analysed with 
primary outcome being incremental cost per primary clinical outcome 
avoided and secondary outcome being incremental cost per QALY gained. 
Utility will be assessed using EuroQol-5 Dimension-5 Level (EQ-5D-5L) with 
United Kingdom (UK) valuation measured at baseline, 3 months, 6 months 
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and 12 months.(15) Patient-level measures of utility derived from the EQ-5D 
instrument will be integrated with survival curves using the quality-adjusted 
survival analysis (QASA) method over the 12-month period.(16) Non-
parametric bootstrapping estimates of mean difference in cost and effects 
(events avoided and QALY gained) from patient level data will be performed 
in order to account for uncertainty due to sampling variation in cost-
effectiveness. “It is recognized that demonstrating a significant reduction in 
QALYs over the 12-month period is not anticipated, but the hypothesised 
impact on avoided MIs suggests that important differences in costs and 
QALYs will not be captured over the trial time horizon. Relevant data sources 
and literature will be sought to extrapolate the longer-term costs and 
benefits derived from observed differences in cardiovascular events to 
generate full estimates of the cost-effectiveness of the 1hr hs-TnT protocol 
compared to the standard 6 hr protocol.” 
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Discussion 
Within Australia, chest pain and suspected ACS represents 10% of the nearly 
8 million ED presentations every year; yet up to 85% of these patients do not 
have ACS.(17)  Importantly, time-consuming assessment may contribute  to 
ED overcrowding, drawing clinical resources away from patients with more 
critical clinical conditions, resulting in increased morbidity and mortality. The 
challenge faced by ED staff focuses on rapid risk assessment to determine 
patient disposition.  Without objective evidence of ischaemia this decision is 
often difficult. It is well understood that evolving ACS cannot be excluded on 
clinical grounds alone, and ECG changes are frequently misinterpreted, with 
nearly half of the patients with MI presenting with normal or nonspecific 
ECG changes.(18,19) Decisions to admit patients without objective coronary 
ischemia for further testing (the majority of patients) are hampered by 
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limited hospital beds and finite testing resources. Of note, the potential for 
unnecessary procedures and iatrogenic harm from the investigation of low-
risk chest pain patients is a significant concern. A US study of 421,774 ED 
presentations demonstrated an increase in MI and revascularization 
associated with several testing strategies when compared with.(20)  
Conversely, the decision to discharge patients early is fraught with the risk of 
missed MI and its attendant consequences.(21)  Unsurprisingly, the resources 
expended to prevent missed MI are substantial.(17) 
Merely reporting troponin results to levels achievable with a high sensitivity 
troponin T assay did not translate to more effective decision-making and 
improved 30 day clinical outcomes, though an unexplained modest 
reduction in 12-month mortality may be evident.(13) Consequently, routine 
hs-TnT reporting was not cost-effective (ICER: $193,135/QALY gained). 
Translating these innovations effectively into routine practice is undeniably 
complex. Therefore, it is not surprising that hs-TnT approval in the United 
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States has only recently occured, while local (Australian Health Technology 
Assessment Agency) and international bodies (i.e. Canada Agency for Drug 
and Technologies in Heath, and NICE in the UK) continue to call for more 
randomized evaluations of the true impacts of decision-making protocols 
integrating high-sensitivity troponin assays. (4,5)   
Several decision rules and risk-scoring algorithms have previously been 
developed to facilitate early discharge for suspected ACS patients.(22,23)  
These protocols have performed well in single-arm, uncontrolled studies, 
but interpreting the effectiveness and cost-effectiveness have been 
hampered by the lack of randomised trials.(23-25) Zero-hour/1-hour 
protocols based on troponin T and I have received particular international 
attention due to their ability to potentially identify up to 60% of patients 
suitable for early discharge at 1 hour.(7,26) Despite continued debate, these 
protocols have been adopted into the European Society of Cardiology (ESC) 
Non ST-segment elevation ACS Guideline.(6)  While promising, their 
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uncontrolled single-arm design leaves several issues that limit confidence in 
their implementation. First, these studies have needed to be selective in their 
patient recruitment, resulting in an under-representation of more complex 
patients.  Second, the patients were not managed in accordance with the 
results, relying on post-hoc analysis of bio-banks. Third, the utility of the 
protocol remains uncertain across the full range of “pre-test probability” for 
ACS observed in clinical practice. This latter point is of particular relevance 
when making patient-specific recommendations based on well-established 
clinical criteria.(19) Fourth, very few patients with MI presented early (within 2 
hours of onset) and the utility of the rule-out recommendations at this early 
timepoint remain uncertain. Fifth, the “rule-in” MI aspects of this protocol 
may be over inclusive and may lead to low-value investigation of patients 
with nonspecific myocardial injury rather than true type 1 MI. While a small 
randomised study of a 0-hour/1-hour (n=542) has demonstrated feasibility 
of early discharge, this study had insufficient power to address clinical 
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events.(27) Furthermore, retrospectively applying the current ESC guideline-
advocated hs-TnT “rule-in/rule-out” criteria to chest pain cohort collected 
across several centres highlights a sub-optimal rule-out performance of a 
hs-TnT protocol with a negative predictive value of 97.1(94.0-98.0)%, 
suggesting that up to 3% of MIs may be missed MI.  
The study has been designed to specifically address the equipoise of key 
decision-makers where evidence is required to support implementation.  
Specifically, clinicians require evidence that subsequent investigation and 
management under such a decision-rule improves overall outcomes in all 
suspected ACS patients. Similarly, emergency physicians require robust 
evidence of the safety of the 0-hour/1-hour protocol in identifying patients 
for discharge, while health service providers require evidence that 
implementing a rapid troponin protocol leads to efficient care. Assay level, 
but not practice level comparisons of 0-hour/1-hour protocols continue to 
show improved diagnostic performance.(7,26,28) While a cluster-randomized 
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trial assessing the impact of a high-sensitivity troponin I assay has been 
initiated, this hospital level randomization may be less efficient for 
interpreting the interaction between the investigational protocol and patient 
risk. Hence, this patient-level randomized controlled design, uniquely 
controlling the reporting of hs-TnT results and blinded-endpoint 
adjudication is essential to interpret impacts on clinical practice, interactions 
with patient risk; evaluate overall effectiveness (and potential iatrogenic 
events); and robustly evaluate efficiency. Prospective and randomized 
comparison of these protocols are warranted before widespread 
implementation can be broadly advocated. 
 
Conclusion 
Challenges in risk-stratifying emergency patients with symptoms of 
suspected acute coronary syndrome may lead to inappropriate discharge 
and missed MI, while unnecessary admission can result in over-investigation 
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and iatrogenic harm. Demonstrating that a rapid hs-TnT protocol improves 
the appropriateness, effectiveness and efficiency of care within a robust 
comparative study will fill a challenging evidence gap that currently limits 
the translation of more precise hs-TnT testing into better patient and health 
service outcomes.  
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Table and Figure Legends 
Table 1: Hospital level and patient level inclusion and exclusion criteria 
Table 2: Study Outcomes Definitions 
Table 3: Characteristics of patients currently randomized 
 
Figure 1: Study schematic with anticipated rates of admission and discharge 
of patients from the Emergency Department, and populations of patients to 
be used to assess study aims. 
Figure 2: Reported performance of rule-in/rule-out M protocol using 0-
Hour/1-Hour high-sensitivity troponin T testing.(7) 
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Table 1: Inclusion criteria: Hospital and Patient Selection Criteria 
Patient Inclusion Criteria Patients presenting to the ED will be eligible if they have: 
a. Clinical features of chest pain or suspected ACS as the principal cause for investigation;  
b. Baseline electrocardiogram (ECG) interpreted as not definitive for coronary ischemia;  
c. Age greater than 18 years of age or older;  
d. are willing to give written informed consent 
Patient Exclusion Criteria Patients will be considered ineligible if they: 
a. Require admission for non-chest pain related reasons; 
b. Are admitted as a result of a transfer from another hospital; 
c. Are representing with chest pain within 30 days of last presentation; 
d. Require permanent dialysis; 
e. Are unable to complete clinical history questionnaire due to language or comorbidity  
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Table 2: Study Outcomes Definitions 
Definitions 
All-cause 
mortality 
 
Death form any cause 
CV Mortality Death due to myocardial infarction, sudden cardiac death, heart failure or cardiogenic shock, 
stroke, and other causes including pulmonary embolism, or aortic aneurysm rupture. 
New/Recurrent 
MI* 
New MI: A rise and/or fall of biomarkers with at least one value above the 99th percentile of 
the URL with at least one of the following(29); 
 Symptoms of ischemia 
 ECG changes indicative of new ischemia, new ST-T changes or new LBBB 
 Development of pathological Q waves in the ECG 
 Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality 
 Sudden unexpected cardiac death, involving cardiac arrest, and accompanied by 
presumably new ST elevation, or new LBBB. 
 Pathological findings of an acute myocardial infarction  
 
Re-MI:  
 In participants without MI at admission, a MI after enrolment but prior to 
angiography will be diagnosed when any elevation of troponin or CK-MB >ULN 
occurs (or CK >ULN in the absence of MB determination). 
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 In participants with MI at presentation, in whom the elevated troponin or CK-MB (or 
CK) levels are documented to be falling or have returned to normal, diagnosis of a 
second MI requires:  
o New elevation of troponin or CK-MB >ULN (or CK >ULN in the absence of MB 
determination) if the troponin or CK-MB (or CK) level has returned to <ULN,  
or 
o Rise by >20% or 50% above the previous nadir level if the troponin or CK-MB 
(or CK) level, respectively, has not returned to <ULN. 
 
 In participants with MI at presentation, in whom the peak troponin or CK-MB (or CK) 
has not yet been reached, diagnosis of a second MI requires: 
o Recurrent chest pain 30 minutes, or 
o New ECG changes consistent with MI, and 
o The next troponin or CK-MB (or CK) level measured approximately 8-12 hours 
after the event be elevated by at least 50% above the previous level. 
 
MI following PCI: cTn values >5 x 99th percentile URL in patients with normal baseline values 
or a rise of cTn values >20% if the baseline values are elevated and are stable or falling and 
either:. 
 Symptoms suggestive of myocardial ischemia; 
 New ischemic ECG changes or new LBBB; or  
 Angiographic loss of patency of a major coronary artery or a side branch or persistent 
slow- or no-flow or embolization, or  
 Imaging demonstration of new loss of viable myocardium or new regional wall 
motion abnormality. 
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MI following CABG: elevation of cardiac biomarker values >10 x 99th percentile URL in 
patients with normal baseline cTn values (>99th percentile URL) and either:  
 New pathological Q waves or new LBBB, or  
 Angiographic documented new graft or new native coronary artery occlusion, or  
 Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality. 
Unstable Angina Chest pain/discomfort with an accelerated pattern or occurring at rest, associated with: 
dynamic ECG changes consistent with ischemia; or functional testing consistent with 
ischemia; and/or demonstrated coronary stenosis>70% by visual estimation. 
Unplanned 
hospital 
admission 
Non-elective coronary revascularization; cerebrovascular accidents; atrial or ventricular 
arrhythmias; congestive cardiac failure without MI; as documented by a hospital discharge 
summary at 30 days and 12 months.  
Bleeding  TIMI Major/minor/minimal bleed:  
 Major: Overt clinical bleeding (or documented intracranial or retroperitoneal 
hemorrhage) associated with a drop in hemoglobin of greater than 5g/dl (50g/l) or a 
hematocrit of greater than 15% (absolute). 
 Minor: overt clinical bleeding associated with a fall in hemoglobin of 3g/dL to 5g/dL 
(50g/l) or a hematocrit of 9% to less than or equal to 15% (absolute). 
 Minimal: Any clinically overt sign of hemorrhage (including imaging) that is 
associated with a <3 g/dl decrease in the hemoglobin concentration or <9% decrease 
in the hematocrit 
 
GUSTO Bleeding Classification 
 Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes 
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hemodynamic compromise and requires intervention 
 Moderate: Bleeding that requires blood transfusion but does not result in 
hemodynamic compromise 
 Mild: Bleeding that does not meet criteria for either severe or moderate bleeding 
 
ACUITY Bleeding Classification 
 Intracranial or intraocular 
 Reduction in Hb of ≥ 4.0 g/dL without an overt source of bleeding, or of ≥ 3.0 g/dL 
with an overt source of bleeding 
 Use of any blood product transfusion 
 Hematoma ≥ 5cm in diameter, re-operation for bleeding, access site hemorrhage 
requiring intervention 
 
Bleeding events will also be classified using the BARC Bleeding Classification(30)  
Health Economic 
Evaluation 
o Measures of in-hospital care: stress testing, echocardiography, coronary angiography, 
cardiac medications at discharge consistent with guidelines  
o Health-related quality of life (EQ-5D-5L) at 30 days, 6 and 12 months  
Resource utilisation over 12 months: Medicare data among consenting patients using 
Medical Benefits Schedule (MBS), medication use from Pharmaceutical Benefits Schedule 
(PBS) and inpatient admissions from the AN-Diagnosis Related Group (DRG) version 6.0. 
* N.B. hs-TnT elevations will undergo blinded adjudication for MI to confirm event time.  All in-hospital MIs occurring during the 
index presentation will be excluded from the primary outcome. Adjudicated MIs will be subclassified using the Third Universal 
definition of MI criteria.(29) 
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Table 3: Characteristics of patients currently randomized 
 
  
Standard 
Protocol 1 Hour Protocol Study Total 
Total (n = 398) (n = 398) (n = 796) 
Age (Mean +/- SD) 57.3 (+/- 17) 57.1 (+/- 16) 57.2 (+/- 16.5) 
Gender = Female (n, %) 180 (45.2%) 171 (43%) 351 (44.1%) 
Diabetes (n, %) 66 (16.6%) 55 (13.8%) 121 (15.2%) 
Hypertension (n, %) 171 (43%) 148 (37.2%) 319 (40.1%) 
Dyslipidaemia (n, %) 114 (28.6%) 109 (27.4%) 223 (28%) 
Current Smoker (n, %) 207 (52%) 213 (53.5%) 420 (52.8%) 
Known CAD (n, %) 81 (20.4%) 87 (21.9%) 168 (21.1%) 
GRACE RS (Median, IQR) 91.6 (70.9, 115.5) 
92.4 (71.4, 
113.8) 91.6 (71.4, 115.3) 
Peak HS Trop T <30ng/L (n, 
%) 340 (85.4%) 343 (86.2%) 683 (85.8%) 
ED LOS (hours) (Median, IQR) 4.5 (3, 6.5) 4.4 (3.3, 6.4) 4.4 (3.2, 6.4) 
Admissions (n, %) 105 (26.4%) 75 (18.8%) 180 (22.6%) 
LOS (hours) (Median, IQR) 5.4 (3.3, 7.7) 4.7 (3.4, 7.4) 5 (3.4, 7.6) 
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Figure 1: Study schematic with anticipated rates of admission and discharge of patients from the Emergency 
Department, and populations of patients to be used to assess study aims. 
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Figure 2: Reported performance of rule-in/rule-out M protocol using 0-Hour/1-Hour high-sensitivity troponin 
T testing.(7) 
 
